Incyte Provides Statement on
Incyte Corporation versus Flexus Biosciences, Inc. Verdict

Wilmington, Del., November 8, 2018 – On November 7, 2018, a jury issued a verdict in the Delaware Superior Court lawsuit brought by Incyte against Flexus, Terry Rosen and Juan Jaen, to protect and defend its intellectual property.

The jury found that all three defendants named in the lawsuit misappropriated an Incyte trade secret.

The jury did not award a remedy for this misappropriation and Incyte will consider all available options, including appeal, if it is deemed appropriate.

Incyte believes that all biopharmaceutical companies and institutions who rely on the work of their scientists to advance innovations for patients have a common interest in protecting and defending their intellectual property. Incyte will continue to strike the proper balance between maintaining the secrecy of competitively important information, and sharing information to advance the march of science to bring new medicines to patients.

As a company committed to research and development, Incyte invests the majority of its operating budget into these efforts, and will continue to protect the valuable data, technology, insights, and ideas generated in each of those programs.

Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this statement, including statements regarding whether and when the Company will pursue any further options in this litigation, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including those risks detailed in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2018. Incyte disclaims any intent or obligation to update these forward-looking statements.

# # #

Media Contact:
Catalina Loveman  +1 302 498 6171
cloveman@incyte.com